Scholarlink

<p>Pulmonary mesenchymal cystic hamartoma (MCH) is an exceptionally rare benign tumor characterized by cystic-solid architecture and biphasic epithelial-mesenchymal components. We report a 56-year-old woman with a 2.6-cm right lower lobe mass, histologically composed of pseudostratified ciliated epithelium, glandular components, and primitive mesenchymal cells with cartilaginous/adipose differentiation. Tumor cells showed diffuse moderate cytoplasmic BCL-2/CD56 staining, weak-moderate nuclear PR positivity, and a low Ki-67 index (&lt; 2%). RNA sequencing identified a novel <i>EWSR1::CREM</i> fusion, involving exon 13 of EWSR1 and intron 5/exon 6 of CREM. This finding expands the molecular spectrum of <i>FET::CREB</i>-driven tumors and distinguishes MCH from mimics such as glomus tumor and pleuropulmonary blastoma. The patient remained recurrence-free at 4-year follow-up, underscoring the benign nature of this lesion. This study highlights three critical insights: (1) Molecular significance: The <i>EWSR1::CREM</i>&#xa0;fusion suggests shared oncogenic mechanisms with intracranial mesenchymal tumors and primary pulmonary myxoid sarcoma. (2) Diagnostic refinement: Integration of molecular profiling resolves diagnostic ambiguity in cystic lung lesions. (3) Clinical relevance: Routine molecular testing should be considered for ambiguous cystic lung lesions to refine classification. Conservative management is appropriate for molecularly confirmed MCH. Our findings emphasize the necessity of integrating histomorphology, immunohistochemistry, and molecular profiling in diagnosing rare pulmonary entities. Further studies are needed to elucidate the role of <i>EWSR1::CREM</i> in MCH pathogenesis and explore targeted therapeutic strategies.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Pulmonary mesenchymal cystic hamartoma with EWSR1::CREM fusion: molecular redefinition and diagnostic implications

  • 期刊论文

  • 发表日期：

    2025年7月4日

查看全文
  • Hao Lei,
  • Xiude Li,
  • Haiqin Zhang,
  • Jing Hu,
  • Xueyue Li,
  • Hongyuan Liao,
  • Xinjian Guo,
  • Xiaofeng Zhou

摘要

Pulmonary mesenchymal cystic hamartoma (MCH) is an exceptionally rare benign tumor characterized by cystic-solid architecture and biphasic epithelial-mesenchymal components. We report a 56-year-old woman with a 2.6-cm right lower lobe mass, histologically composed of pseudostratified ciliated epithelium, glandular components, and primitive mesenchymal cells with cartilaginous/adipose differentiation. Tumor cells showed diffuse moderate cytoplasmic BCL-2/CD56 staining, weak-moderate nuclear PR positivity, and a low Ki-67 index (< 2%). RNA sequencing identified a novel EWSR1::CREM fusion, involving exon 13 of EWSR1 and intron 5/exon 6 of CREM. This finding expands the molecular spectrum of FET::CREB-driven tumors and distinguishes MCH from mimics such as glomus tumor and pleuropulmonary blastoma. The patient remained recurrence-free at 4-year follow-up, underscoring the benign nature of this lesion. This study highlights three critical insights: (1) Molecular significance: The EWSR1::CREM fusion suggests shared oncogenic mechanisms with intracranial mesenchymal tumors and primary pulmonary myxoid sarcoma. (2) Diagnostic refinement: Integration of molecular profiling resolves diagnostic ambiguity in cystic lung lesions. (3) Clinical relevance: Routine molecular testing should be considered for ambiguous cystic lung lesions to refine classification. Conservative management is appropriate for molecularly confirmed MCH. Our findings emphasize the necessity of integrating histomorphology, immunohistochemistry, and molecular profiling in diagnosing rare pulmonary entities. Further studies are needed to elucidate the role of EWSR1::CREM in MCH pathogenesis and explore targeted therapeutic strategies.